Mismatch repair deficient endometrial cancer / uterine cancer
Conditions
Brief summary
The main study endpoint is the fraction of patients that achieve a MPR. that the study is considered positive if neo-adjuvant pembrolizumab induces MPRs in at least 74% of patients.
Detailed description
The objective response rate of the tumor determined by radiologic assessment using MRI and RECIST1.1., Recurrence-free survival 2 years from disease diagnosis., The safety and tolerability of 9 cycles of neo-adjuvant pembrolizumab in the treatment of MMRd UC.
Interventions
DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| The objective response rate of the tumor determined by radiologic assessment using MRI and RECIST1.1., Recurrence-free survival 2 years from disease diagnosis., The safety and tolerability of 9 cycles of neo-adjuvant pembrolizumab in the treatment of MMRd UC. | — |
Primary
| Measure | Time frame |
|---|---|
| The main study endpoint is the fraction of patients that achieve a MPR. that the study is considered positive if neo-adjuvant pembrolizumab induces MPRs in at least 74% of patients. | — |
Countries
Netherlands
Outcome results
None listed